Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
Masafumi Ikeda(National Cancer Center Hospital East), Hiroshi Horio(Sumitomo Dainippon Pharma (Japan)), Hiroaki Nagamatsu, Masatoshi Kudo(Kindai University), Hiroshi Aikata(Hiroshima Prefectural Hospital), Tosiya Sato(Ogikubo Hospital), Hiroshi Ishii(Chiba Cancer Center), Toru Yamashita(Okayama University), Takuji Okusaka(National Cancer Centre Japan), Ikuko Kawai(Sumitomo Dainippon Pharma (Japan)), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Osamu Yokosuka(Chiba University), Kenji Ikeda(Toranomon Hospital), Takuji Torimura(Omuta hospital), Hiromitsu Kumada(Toranomon Hospital)
Cited by 91
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k